Clinical trial
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or…
NCT00337168 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00337168 |
|---|---|
| Title | S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Official title | A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | clofarabine, cytarabine |
| Enrollment | 36 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2013 |
| First posted | Jun 15, 2006 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: